---
title: Regdanvimab
slug: regdanvimab
qid: 
snapshot: enwiki-001338742550
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1338742550
tags: [101541378, 106462793, 20503538, 22899184, 22961512, 23118434, 23603337, 24409354, 26220375, 27293495, 40590544, 50769796, 61955657, 68150358, 68328988, 70502559, 71602501, 71642683]
---

# Regdanvimab

> [!note] Provenance
> Snapshot `enwiki-001338742550` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1338742550> · Licensed CC BY-SA 4.0

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was authorized for medical use in the European Union in November 2021.

Regdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein. The most common side effects include infusion-related reactions, including allergic reactions and anaphylaxis. Regdanvimab was authorized for medical use in the European Union in November 2021.
